{"contacts": [{"terms": [{"accession": "MS:1000586", "name": "contact name", "value": "James Duncan"}, {"accession": "MS:1000589", "name": "contact email", "value": "james.s.duncan@fccc.edu"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Fox Chase Cancer Center"}, {"accession": "MS:1002037", "name": "dataset submitter"}]}, {"terms": [{"accession": "MS:1002332", "name": "lab head"}, {"accession": "MS:1000586", "name": "contact name", "value": "James Stuart Duncan"}, {"accession": "MS:1000589", "name": "contact email", "value": "james.duncan2@fccc.edu"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Cancer Biology Department, Fox Chase Cancer Center, Philadelphia, PA, USA"}]}], "datasetFiles": [{"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/02/PXD015782/170623_Q1_AK_HKS_OVCAR4_siCDC42_A_phospho.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/02/PXD015782/170623_Q1_AK_HKS_OVCAR4_siCDC42_A_phospho_170629114840.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/02/PXD015782/170623_Q1_AK_HKS_OVCAR4_siCDC42_B_phospho.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/02/PXD015782/170623_Q1_AK_HKS_OVCAR4_siCDC42_B_phospho_170629233725.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/02/PXD015782/170623_Q1_AK_HKS_OVCAR4_siNT2_A_phospho_170627061547.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/02/PXD015782/170623_Q1_AK_HKS_OVCAR4_siNT2_A_phospho_170627104003.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/02/PXD015782/170623_Q1_AK_HKS_OVCAR4_siNT2_B_phospho.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/02/PXD015782/170623_Q1_AK_HKS_OVCAR4_siNT2_B_phospho_170627222847.raw"}, {"accession": "MS:1002850", "name": "Peak list file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/02/PXD015782/andromeda.zip"}, {"accession": "MS:1002851", "name": "Other type file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/02/PXD015782/experimentalDesignTemplate.txt"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/02/PXD015782/txt.zip"}], "description": "High-grade serous ovarian carcinoma (HGSOC) is the most lethal gynecological cancer with few effective targeted therapies. HGSOC tumors exhibit genomic instability with frequent alterations in the protein kinome; however, only a small fraction of the kinome has been therapeutically targeted in HGSOC. Using multiplexed inhibitor beads and mass spectrometry (MIB-MS), we mapped the kinome landscape of HGSOC patient tumors and tumors isolated from HGSOC patient-derived xenograft (PDX) models.  Kinome profiling of HGSOC tumors uncovered a prevalent MIB-MS kinome signature consisting of established HGSOC driver kinases, as well as several kinases previously unexplored in HGSOC.  Loss-of-function analysis targeting the tumor kinome signature in HGSOC cells nominated CDC42BPA (also known as MRCKA) as a putative therapeutic target.  Characterization of MRCKA knockdown in established HGSOC cell lines demonstrated MRCKA was integral to signaling that regulated the cell cycle checkpoint and focal adhesion/ actin remodeling, and depletion of MRCKA impaired cell migration, proliferation and survival.  Moreover, small molecule inhibition of MRCKA using BDP9066 inhibited cell growth and induced apoptosis in HGSOC cells, as well as blocked spheroid formation, supporting MRCKA as a novel therapeutic target for the treatment of HGSOC.", "fullDatasetLinks": [{"accession": "MS:1002852", "name": "Dataset FTP location", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/02/PXD015782"}, {"accession": "MS:1001930", "name": "PRIDE project URI", "value": "http://www.ebi.ac.uk/pride/archive/projects/PXD015782"}], "identifiers": [{"accession": "MS:1001919", "name": "ProteomeXchange accession number", "value": "PXD015782"}], "instruments": [{"accession": "MS:1001911", "name": "Q Exactive"}], "keywords": [{"accession": "MS:1001925", "name": "submitter keyword", "value": "Human, High Grade Serous Ovarian Carcinoma, MRCKA, CDC42BPA"}], "modifications": [{"accession": "MOD:00696", "name": "phosphorylated residue"}, {"accession": "MOD:00544", "name": "6x(13)C labeled residue"}, {"accession": "MOD:00394", "name": "acetylated residue"}, {"accession": "MOD:00425", "name": "monohydroxylated residue"}, {"accession": "MOD:00397", "name": "iodoacetamide derivatized residue"}], "publications": [{"terms": [{"accession": "MS:1002858", "name": "Dataset with its publication pending"}]}], "species": [{"terms": [{"accession": "MS:1001469", "name": "taxonomy: scientific name", "value": "Homo sapiens (Human)"}, {"accession": "MS:1001467", "name": "taxonomy: NCBI TaxID", "value": "9606"}]}], "title": "Identification of MRCKA as an integral component of ovarian cancer signaling and a therapeutic target"}